Article Text

PDF
THU0155 The addition of another disease-modifying anti-rheumatic drug to methotrexate in place of infliximab improves the rate of infliximab-free sustained remission
  1. T. Kurasawa1,
  2. H. Nagasawa1,
  3. K. Amano1,
  4. T. Takeuchi2,
  5. H. Kameda2
  1. 1Department of Rheumatology/Clinical Immunology, Saitama Medical Center, Kawagoe
  2. 2Rheumatology/Clinical immunology, Department of internal Medicine, Faculty of Medicine, Keio University, Tokyo, Japan

Abstract

Background Anti-tumor necrosis factor (TNF) biological agent, infliximab, (IFX) has been successfully withdrawn in at least a half of patients with rheumatoid arthritis (RA) in sustained remission with IFX plus methotrexate (MTX) [1].

Objectives We examined whether the addition of another inexpensive disease-modifying anti-rheumatic drug (DMARD) to MTX in place of IFX decrease the rate of disease flare after discontinuing IFX in well-controlled RA patients. The BuSHIDO (Bucillamine Study of Holding remission after Infliximab Dose-Off) trial is the prospective, randomized, controlled study comparing MTX monotherapy with MTX plus bucillamine, a DMARD structurally related to D-penicillamine [2], as to flare rate in the following 2 years.

Methods RA patients who had been receiving 6 or more infusions of IFX, reaching DAS28-ESR <3.2 or DAS28-CRP <2.6 for more than 6 months were randomized to either bucillamine 200 mg/day added to MTX (group 1) or MTX alone (group 2) upon discontinuing IFX. Primary endpoint was the flare rate (DAS28-ESR >3.2 and DAS28-CRP >2.6) within 2 years.

Results The study has been completed at the end of December 2011. Finally, 24 and 31 patients were assigned to group 1 and 2, respectively. Four patients experienced flares in group 1, while 17 patients did in group 2. However, bucillamine treatment was discontinued in seven patients in group 1 because of rash (n=5), proteinuria (n=1) and incompliance (n=1). Among those seven patients, three patients experienced disease flare. MTX treatment was discontinued in four patients because of incompliance. Thus, the flare rates were 26.7% in bucillamine-continuing patients, 42.9% in bucillamine-discontinuing patients, and 63.0% in MTX-alone (group 2) patients, which is significantly higher than MTX plus bucillamine (group 1) patients (p=0.045). The mean radiographic progression assessed by modified Sharp score was 0.2 in group 1, and 0.7 in group 2, respectively (p=0.51). In addition, the multivariate analysis revealed that a stringent control of RA activity upon IFX discontinuation and the addition of bucillamine were the factors independently contributing to the IFX-free disease control.

Conclusions A DMARD-combination therapy, such as bucillamine plus MTX may be useful for maintaining disease remission after the remission induction by anti-TNF biological agents.

  1. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010;69:1286 - 1291.

  2. Ichikawa Y, Saito T, Yamanaka H, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol 2005;15:323 - 328.

Disclosure of Interest T. Kurasawa: None Declared, H. Nagasawa: None Declared, K. Amano: None Declared, T. Takeuchi Grant/Research support from: Mitsubisi Tanabe Pharma, H. Kameda: None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.